{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:02:29Z","timestamp":1787792549620,"version":"build-2784847793"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00787-024-02637-x","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T13:59:09Z","timestamp":1734962349000},"page":"1719-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging therapeutic approaches for Tourette syndrome and other tic disorders \u2013 a systematic review of current clinical trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Alexander","family":"H\u00e4ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dunlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Mechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2637_CR1","unstructured":"APA (2013) Diagnostic and statistical manual of mental disorders, 5th ed"},{"key":"2637_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pediatrneurol.2022.08.010","volume":"137","author":"F Jafari","year":"2022","unstructured":"Jafari F, Abbasi P, Rahmati M, Hodhodi T, Kazeminia M (2022) Systematic review and Meta-analysis of Tourette Syndrome Prevalence; 1986 to 2022. Pediatr Neurol 137:6\u201316","journal-title":"Pediatr Neurol"},{"key":"2637_CR3","unstructured":"WHO ICD-11: International classification of diseases (11th revision)2022"},{"issue":"4","key":"2637_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40474-016-0099-1","volume":"3","author":"A Kumar","year":"2016","unstructured":"Kumar A, Trescher W, Byler D (2016) Tourette Syndrome and Comorbid Neuropsychiatric conditions. Curr Dev Disord Rep 3(4):217\u2013221","journal-title":"Curr Dev Disord Rep"},{"key":"2637_CR5","doi-asserted-by":"crossref","unstructured":"Lee WT, Huang HL, Wong LC, Weng WC, Vasylenko T, Jong YJ et al (2017) Tourette Syndrome as an independent risk factor for subsequent Sleep disorders in children: a Nationwide Population-based case-control study. Sleep. 40(3)","DOI":"10.1093\/sleep\/zsw072"},{"issue":"7","key":"2637_CR6","first-page":"101032","volume":"51","author":"KK Set","year":"2021","unstructured":"Set KK, Warner JN (2021) Tourette syndrome in children: an update. Curr Probl Pediatr Adolesc Health Care 51(7):101032","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"19","key":"2637_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K, Martino D, Jankovic J, Cavanna AE et al (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896\u2013906","journal-title":"Neurology"},{"issue":"3","key":"2637_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00787-021-01832-4","volume":"31","author":"KR M\u00fcller-Vahl","year":"2022","unstructured":"M\u00fcller-Vahl KR, Szejko N, Verdellen C, Roessner V, Hoekstra PJ, Hartmann A et al (2022) European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry 31(3):377\u2013382","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"2637_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00787-021-01845-z","volume":"31","author":"P Andr\u00e9n","year":"2022","unstructured":"Andr\u00e9n P, Jakubovski E, Murphy TL, Woitecki K, Tarnok Z, Zimmerman-Brenner S et al (2022) European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part II: psychological interventions. Eur Child Adolesc Psychiatry 31(3):403\u2013423","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"2637_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","volume":"31","author":"V Roessner","year":"2022","unstructured":"Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM et al (2022) European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 31(3):425\u2013441","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"9","key":"2637_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R et al (2017) Randomized, Double-Blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27(9):771\u2013781","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"2637_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11910-022-01177-8","volume":"22","author":"J Frey","year":"2022","unstructured":"Frey J, Malaty IA (2022) Tourette Syndrome Treatment Updates: a review and discussion of the current and upcoming literature. Curr Neurol Neurosci Rep 22(2):123\u2013142","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2637_CR13","unstructured":"WHO https:\/\/trialsearch.who.int 2024"},{"key":"2637_CR14","unstructured":"NIH https:\/\/www.clinicaltrials.gov 2024"},{"issue":"5","key":"2637_CR15","first-page":"401","volume":"25","author":"MF Seideman","year":"2020","unstructured":"Seideman MF, Seideman TA (2020) A review of the current treatment of Tourette Syndrome. J Pediatr Pharmacol Ther 25(5):401\u2013412","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2637_CR16","doi-asserted-by":"crossref","unstructured":"Ueda K, Black KJ (2021) A Comprehensive Review of Tic disorders in Children. J Clin Med. 10(11)","DOI":"10.3390\/jcm10112479"},{"issue":"1","key":"2637_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/brain\/aww285","volume":"140","author":"AS Kanaan","year":"2017","unstructured":"Kanaan AS, Gerasch S, Garc\u00eda-Garc\u00eda I, Lampe L, Pampel A, Anwander A et al (2017) Pathological glutamatergic neurotransmission in Gilles De La Tourette syndrome. Brain 140(1):218\u2013234","journal-title":"Brain"},{"issue":"8","key":"2637_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1515\/revneuro-2022-0035","volume":"33","author":"S Nikolaus","year":"2022","unstructured":"Nikolaus S, Mamlins E, Antke C, Dabir M, M\u00fcller HW, Giesel FL (2022) Boosted dopamine and blunted serotonin in Tourette syndrome - evidence from in vivo imaging studies. Rev Neurosci 33(8):859\u2013876","journal-title":"Rev Neurosci"},{"key":"2637_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pscychresns.2017.12.005","volume":"273","author":"EM Mahone","year":"2018","unstructured":"Mahone EM, Puts NA, Edden RAE, Ryan M, Singer HS (2018) GABA and glutamate in children with Tourette syndrome: A (1)H MR spectroscopy study at 7T. Psychiatry Res Neuroimaging 273:46\u201353","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2637_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuropharm.2015.08.019","volume":"106","author":"M Rapanelli","year":"2016","unstructured":"Rapanelli M, Pittenger C (2016) Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacology 106:85\u201390","journal-title":"Neuropharmacology"},{"issue":"8","key":"2637_CR21","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","volume":"45","author":"KR M\u00fcller-Vahl","year":"2020","unstructured":"M\u00fcller-Vahl KR, Bindila L, Lutz B, Musshoff F, Skripuletz T, Baumgaertel C et al (2020) Cerebrospinal fluid endocannabinoid levels in Gilles De La Tourette syndrome. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol 45(8):1323\u20131329","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"key":"2637_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5334\/tohm.442","volume":"8","author":"F Augustine","year":"2018","unstructured":"Augustine F, Singer HS (2018) Merging the pathophysiology and pharmacotherapy of tics. Tremor Other Hyperkinet Mov (N Y) 8:595","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"1","key":"2637_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","volume":"37","author":"DL Gilbert","year":"2014","unstructured":"Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (2014) A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 37(1):26\u201330","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"2637_CR24","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.27457","volume":"33","author":"DL Gilbert","year":"2018","unstructured":"Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM et al (2018) Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord 33(8):1272\u20131280","journal-title":"Mov Disord"},{"key":"2637_CR25","doi-asserted-by":"crossref","unstructured":"Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR (2023) Ecopipam for Tourette Syndrome: a Randomized Trial. Pediatrics. 151(2)","DOI":"10.1542\/peds.2022-059574"},{"key":"2637_CR26","unstructured":"Garibaldi G, Lasser R, Mueller-Vahl K (2024) Results of ALLEVIA 1, a phase 2a study exploring safety and tolerability of NOE-105 in patients with Tourette Syndrome. MDS Congress; September 27 - October 1, 2024; Philadelphia, PA, USA2024."},{"key":"2637_CR27","doi-asserted-by":"crossref","unstructured":"Marshall RD, Menniti FS, Tepper MA (2024) A novel PDE10A inhibitor for Tourette Syndrome and Other Movement disorders. Cells. 13(14)","DOI":"10.3390\/cells13141230"},{"issue":"4","key":"2637_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2018.0050","volume":"4","author":"LM Milosev","year":"2019","unstructured":"Milosev LM, Psathakis N, Szejko N, Jakubovski E, M\u00fcller-Vahl KR (2019) Treatment of Gilles De La Tourette syndrome with Cannabis-Based Medicine: results from a retrospective analysis and online survey. Cannabis Cannabinoid Res 4(4):265\u2013274","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"2637_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-2256-0098","volume":"57","author":"KR M\u00fcller-Vahl","year":"2024","unstructured":"M\u00fcller-Vahl KR (2024) Cannabinoids in the treatment of selected Mental illnesses: practical Approach and Overview of the literature. Pharmacopsychiatry 57(3):104\u2013114","journal-title":"Pharmacopsychiatry"},{"key":"2637_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fpsyt.2020.00859","volume":"11","author":"G Blest-Hopley","year":"2020","unstructured":"Blest-Hopley G, Colizzi M, Giampietro V, Bhattacharyya S (2020) Is the adolescent brain at Greater vulnerability to the effects of Cannabis? A narrative review of the evidence. Front Psychiatry 11:859","journal-title":"Front Psychiatry"},{"issue":"10","key":"2637_CR31","doi-asserted-by":"publisher","first-page":"e2128204","DOI":"10.1001\/jamanetworkopen.2021.28204","volume":"4","author":"J Jankovic","year":"2021","unstructured":"Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA et al (2021) Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette Syndrome: a Randomized Clinical Trial. JAMA Netw Open 4(10):e2128204","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2637_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737175.2021.1898948","volume":"21","author":"RH Farber","year":"2021","unstructured":"Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E (2021) Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother 21(4):393\u2013404","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"2637_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/070674371205700303","volume":"57","author":"T Steeves","year":"2012","unstructured":"Steeves T, McKinlay BD, Gorman D, Billinghurst L, Day L, Carroll A et al (2012) Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry Revue canadienne de psychiatrie 57(3):144\u2013151","journal-title":"Can J Psychiatry Revue canadienne de psychiatrie"},{"key":"2637_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2019.12.015","volume":"106","author":"HS Singer","year":"2020","unstructured":"Singer HS, McDermott S, Ferenc L, Specht M, Mahone EM (2020) Efficacy of Parent-Delivered, Home-based therapy for tics. Pediatr Neurol 106:17\u201323","journal-title":"Pediatr Neurol"},{"issue":"2","key":"2637_CR35","doi-asserted-by":"publisher","first-page":"e024685","DOI":"10.1136\/bmjopen-2018-024685","volume":"9","author":"P Andr\u00e9n","year":"2019","unstructured":"Andr\u00e9n P, Aspvall K, de la Fern\u00e1ndez L, Wiktor P, Romano S, Andersson E et al (2019) Therapist-guided and parent-guided internet-delivered behaviour therapy for paediatric Tourette\u2019s disorder: a pilot randomised controlled trial with long-term follow-up. BMJ open 9(2):e024685","journal-title":"BMJ open"},{"issue":"3","key":"2637_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cbpra.2017.01.003","volume":"24","author":"CA Conelea","year":"2017","unstructured":"Conelea CA, Wellen BCM (2017) Tic Treatment goes tech: a review of TicHelper.com. Cogn Behav Pract 24(3):374\u2013381","journal-title":"Cogn Behav Pract"},{"key":"2637_CR37","doi-asserted-by":"crossref","unstructured":"Prato A, Maugeri N, Chiarotti F, Morcaldi L, Vicario CM, Barone R et al (2022) A Randomized Controlled Trial Comparing Videoconference vs. Face-to-Face Delivery of Behavior Therapy for Youths With Tourette Syndrome in the Time of COVID-19. Front Psychiatry. 13:862422","DOI":"10.3389\/fpsyt.2022.862422"},{"key":"2637_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fpsyt.2016.00119","volume":"7","author":"E Jakubovski","year":"2016","unstructured":"Jakubovski E, Reichert C, Karch A, Buddensiek N, Breuer D, M\u00fcller-Vahl K (2016) The ONLINE-TICS study protocol: a Randomized Observer-Blind Clinical Trial to demonstrate the efficacy and safety of internet-delivered behavioral treatment for adults with chronic Tic disorders. Front Psychiatry 7:119","journal-title":"Front Psychiatry"},{"issue":"3","key":"2637_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jpsychores.2014.08.001","volume":"78","author":"HE Reese","year":"2015","unstructured":"Reese HE, Vallejo Z, Rasmussen J, Crowe K, Rosenfield E, Wilhelm S (2015) Mindfulness-based stress reduction for Tourette Syndrome and chronic tic disorder: a pilot study. J Psychosom Res 78(3):293\u2013298","journal-title":"J Psychosom Res"},{"key":"2637_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-020-0183-7","volume":"9","author":"W Xu","year":"2020","unstructured":"Xu W, Zhang C, Deeb W, Patel B, Wu Y, Voon V et al (2020) Deep brain stimulation for Tourette\u2019s syndrome. Transl Neurodegener 9:4","journal-title":"Transl Neurodegener"},{"issue":"10","key":"2637_CR41","doi-asserted-by":"publisher","first-page":"e10952","DOI":"10.1016\/j.heliyon.2022.e10952","volume":"8","author":"X Lin","year":"2022","unstructured":"Lin X, Lin F, Chen H, Weng Y, Wen J, Ye Q et al (2022) Comparison of efficacy of deep brain stimulation, repeat transcranial magnetic stimulation, and behavioral therapy in Tourette syndrome: a systematic review and Bayesian Network Meta-Analysis. Heliyon 8(10):e10952","journal-title":"Heliyon"},{"key":"2637_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jpsychires.2022.05.025","volume":"151","author":"ZQ Cui","year":"2022","unstructured":"Cui ZQ, Wang J, Mao ZQ, Pan LS, Jiang C, Gao QY et al (2022) Long-term efficacy, prognostic factors, and safety of deep brain stimulation in patients with refractory Tourette syndrome: a single center, single target, retrospective study. J Psychiatr Res 151:523\u2013530","journal-title":"J Psychiatr Res"},{"issue":"11","key":"2637_CR43","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1007\/s00415-022-11266-w","volume":"269","author":"L Dai","year":"2022","unstructured":"Dai L, Xu W, Song Y, Huang P, Li N, Hollunder B et al (2022) Subthalamic deep brain stimulation for refractory Gilles De La Tourette\u2019s syndrome: clinical outcome and functional connectivity. J Neurol 269(11):6116\u20136126","journal-title":"J Neurol"},{"issue":"2","key":"2637_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00221-021-06229-y","volume":"240","author":"K Dyke","year":"2022","unstructured":"Dyke K, Jackson G, Jackson S (2022) Non-invasive brain stimulation as therapy: systematic review and recommendations with a focus on the treatment of Tourette syndrome. Exp Brain Res 240(2):341\u2013363","journal-title":"Exp Brain Res"},{"issue":"4\u20136","key":"2637_CR45","first-page":"11","volume":"19","author":"AM Bejenaru","year":"2022","unstructured":"Bejenaru AM, Malhi NK (2022) Use of Repetitive Transcranial Magnetic Stimulation in Child Psychiatry. Innov Clin Neurosci 19(4\u20136):11\u201322","journal-title":"Innov Clin Neurosci"},{"key":"2637_CR46","doi-asserted-by":"crossref","unstructured":"Iverson AM, Arbuckle AL, Song DY, Bihun EC, Black KJ (2023) Median nerve stimulation for treatment of tics: a 4-Week Open Trial with Ecological Momentary Assessment. J Clin Med. 12(7)","DOI":"10.3390\/jcm12072545"},{"key":"2637_CR47","doi-asserted-by":"publisher","first-page":"826","DOI":"10.12688\/f1000research.135702.1","volume":"12","author":"A Hartmann","year":"2023","unstructured":"Hartmann A, Andr\u00e9n P, Atkinson-Cl\u00e9ment C, Czernecki V, Delorme C, Monique Debes NM et al (2023) Tourette syndrome research highlights from 2022. F1000Res 12:826","journal-title":"F1000Res"},{"issue":"1","key":"2637_CR48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s13063-022-06802-y","volume":"23","author":"SX Guo","year":"2022","unstructured":"Guo SX, Li RB, Hu SY, Cai QH, Zhong CL, Hao RM (2022) Efficacy and safety of Jiu-Wei-Xi-Feng granules for treating tic disorders in children: study protocol for a randomized controlled equivalence trial. Trials 23(1):898","journal-title":"Trials"},{"key":"2637_CR49","doi-asserted-by":"publisher","first-page":"6630598","DOI":"10.1155\/2021\/6630598","volume":"2021","author":"N Wang","year":"2021","unstructured":"Wang N, Qin DD, Xie YH, Wu XC, Wang DY, Hang Y et al (2021) Traditional Chinese Medicine Strategy for patients with Tourette Syndrome based on clinical efficacy and safety: a Meta-analysis of 47 randomized controlled trials. Biomed Res Int 2021:6630598","journal-title":"Biomed Res Int"},{"issue":"3","key":"2637_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000524377","volume":"30","author":"M Kong","year":"2023","unstructured":"Kong M, Yan S, Gao Y, Li H (2023) Is traditional Chinese Medicine Effective in treating Tic disorders (Tourette Syndrome)? A Meta-analysis of Randomized controlled trials. Complement Med Res 30(3):248\u2013257","journal-title":"Complement Med Res"},{"issue":"29","key":"2637_CR51","doi-asserted-by":"publisher","first-page":"e34268","DOI":"10.1097\/MD.0000000000034268","volume":"102","author":"K Lin","year":"2023","unstructured":"Lin K, Wang Y, Wang J, Zhang C, Feng Q (2023) Treatment of Tourette syndrome by acupuncture combined with Chinese medicine based on syndrome differentiation: a review. Med (Baltim) 102(29):e34268","journal-title":"Med (Baltim)"},{"issue":"46","key":"2637_CR52","doi-asserted-by":"publisher","first-page":"15490","DOI":"10.1523\/JNEUROSCI.3299-14.2014","volume":"34","author":"EA Mayer","year":"2014","unstructured":"Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K (2014) Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 34(46):15490\u201315496","journal-title":"J Neurosci"},{"key":"2637_CR53","doi-asserted-by":"crossref","unstructured":"Andrioaie IM, Duhaniuc A, Nastase EV, Iancu LS, Lunc\u0103 C, Trofin F et al (2022) The role of the gut Microbiome in Psychiatric disorders. Microorganisms. 10(12)","DOI":"10.3390\/microorganisms10122436"},{"issue":"1","key":"2637_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12888-020-02654-5","volume":"20","author":"A Chinna Meyyappan","year":"2020","unstructured":"Chinna Meyyappan A, Forth E, Wallace CJK, Milev R (2020) Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. BMC Psychiatry 20(1):299","journal-title":"BMC Psychiatry"},{"key":"2637_CR55","doi-asserted-by":"publisher","first-page":"110258","DOI":"10.1016\/j.pnpbp.2021.110258","volume":"109","author":"CR Settanni","year":"2021","unstructured":"Settanni CR, Ianiro G, Bibb\u00f2 S, Cammarota G, Gasbarrini A (2021) Gut microbiota alteration and modulation in psychiatric disorders: current evidence on fecal microbiota transplantation. Prog Neuropsychopharmacol Biol Psychiatry 109:110258","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2637_CR56","doi-asserted-by":"publisher","first-page":"554441","DOI":"10.3389\/fpsyt.2020.554441","volume":"11","author":"HJ Zhao","year":"2020","unstructured":"Zhao HJ, Luo X, Shi YC, Li JF, Pan F, Ren RR et al (2020) The efficacy of fecal microbiota transplantation for children with Tourette Syndrome: a preliminary study. Front Psychiatry 11:554441","journal-title":"Front Psychiatry"},{"issue":"6","key":"2637_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/CM9.0000000000001885","volume":"135","author":"H Li","year":"2022","unstructured":"Li H, Wang Y, Zhao C, Liu J, Zhang L, Li A (2022) Fecal transplantation can alleviate tic severity in a Tourette syndrome mouse model by modulating intestinal flora and promoting serotonin secretion. Chin Med J (Engl) 135(6):707\u2013713","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"2637_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40474-018-0137-2","volume":"5","author":"A Kumar","year":"2018","unstructured":"Kumar A, Duda L, Mainali G, Asghar S, Byler D (2018) A Comprehensive Review of Tourette Syndrome and complementary Alternative Medicine. Curr Dev Disord Rep 5(2):95\u2013100","journal-title":"Curr Dev Disord Rep"},{"key":"2637_CR59","doi-asserted-by":"crossref","unstructured":"Rizzo R, Prato A, Scerbo M, Saia F, Barone R, Curatolo P (2022) Use of Nutritional supplements based on L-Theanine and vitamin B6 in children with Tourette Syndrome, with anxiety disorders: a pilot study. Nutrients. 14(4)","DOI":"10.3390\/nu14040852"},{"issue":"1","key":"2637_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/19390211.2021.1958120","volume":"20","author":"BL Smith","year":"2023","unstructured":"Smith BL, Ludlow AK (2023) Patterns of Nutritional supplement use in children with Tourette Syndrome. J Diet Suppl 20(1):28\u201343","journal-title":"J Diet Suppl"},{"key":"2637_CR61","first-page":"e068791","volume":"377","author":"KE Hunter","year":"2022","unstructured":"Hunter KE, Webster AC, Page MJ, Willson M, McDonald S, Berber S et al (2022) Searching clinical trials registers: guide for systematic reviewers. BMJ (Clinical Res ed) 377:e068791","journal-title":"BMJ (Clinical Res ed)"},{"key":"2637_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fnins.2016.00133","volume":"10","author":"E Nespoli","year":"2016","unstructured":"Nespoli E, Rizzo F, Boeckers TM, Hengerer B, Ludolph AG (2016) Addressing the complexity of Tourette\u2019s syndrome through the Use of Animal models. Front Neurosci 10:133","journal-title":"Front Neurosci"},{"issue":"10","key":"2637_CR63","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG (2022) Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev 3(10):e674\u2013e89","journal-title":"Lancet Healthy Longev"},{"issue":"11","key":"2637_CR64","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1111\/ene.15034","volume":"28","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Martino D (2021) Rapid onset of functional tic-like behaviours in young adults during the COVID-19 pandemic. Eur J Neurol 28(11):3805\u20133808","journal-title":"Eur J Neurol"},{"key":"2637_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm11216470","volume":"11","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Anderson S, Bennett SM, Budman CL, Coffey BJ, Coffman KA et al (2022) Diagnosis and management of Functional Tic-Like Phenomena. J Clin Med 11:21","journal-title":"J Clin Med"},{"issue":"3","key":"2637_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mdc3.13932","volume":"11","author":"KR M\u00fcller-Vahl","year":"2024","unstructured":"M\u00fcller-Vahl KR, Pisarenko A, Fremer C, Haas M, Jakubovski E, Szejko N (2024) Functional Tic-Like behaviors: a common comorbidity in patients with Tourette Syndrome. Mov Disord Clin Pract 11(3):227\u2013237","journal-title":"Mov Disord Clin Pract"},{"key":"2637_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.neubiorev.2021.08.001","volume":"129","author":"J Garris","year":"2021","unstructured":"Garris J, Quigg M (2021) The female Tourette patient: sex differences in Tourette disorder. Neurosci Biobehav Rev 129:261\u2013268","journal-title":"Neurosci Biobehav Rev"},{"key":"2637_CR68","doi-asserted-by":"crossref","unstructured":"Dy-Hollins ME, Chibnik LB, Tracy NA, Osiecki L, Budman CL, Cath DC et al (2024) Sex differences in people with Tourette Syndrome and Persistent Motor or vocal tic disorder in the Tourette Association. of America International Consortium for Genetics Database. medRxiv","DOI":"10.1101\/2024.01.07.24300816"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-024-02637-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:02:09Z","timestamp":1750831329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-024-02637-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1007\/s00787-024-02637-x","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander H\u00e4ge has received compensation for serving as consultant or speaker for Shire\u2013Takeda and Medice, unrelated to this work. In addition to serving as an investigator in various pharmaceutical trials accross different indications, he is currently a principle investigator for a Tourette study on ecopipam sponsored by Emalex. Konstantin Mechler has received compensation for serving as consultant or speaker for Takeda and Medice, unrelated to this work. In addition to serving as an investigator in various pharmaceutical trials accross different indications, he is currently an investigator for a Tourette study on ecopipam sponsored by Emalex. Kirsten R M\u00fcller-Vahl has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), DFG: GZ MU 1527\/3-1 and GZ MU 1527\/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V., Else-Kr\u00f6ner-Fresenius-Stiftung, GW pharmaceuticals, Almirall, Abide Therapeutics, Emalex Biosciences, Inc., Noema Pharma, CannaXan, and Therapix Biosiences.She has received consultant's and other honoraria from Abide Therapeutics, adjupharm, Alexion, AlphaSights Ltd., AMP Alternative Medical Products GmbH, Asavita GmbH, Becanex, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., DHMS Direct Health Medical Services Ltd., Demecan, Enua pharma, DHMS Direct Health Medical Services Ltd., Ethypharm GmbH, Eurox Group, Global Praxis Group Limited, Hormosan Pharma GmbH, Lundbeck, Marry Jane, MCI Germany, Neuraxpharm, Noema Pharma, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe, Tilray, and Zambon. She is an advisory\/scientific board member for Alexion, Branchenverband Cannabiswirtschaft e.V. (BvCW), CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, Ethypharm GmbH, Hormosan Pharma GmbH, IMC Germany, Leafly Deutschland GmbH, Neuraxpharm, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe Medical Ltd., Therapix Biosciences Ltd., and Tilray. She has received speaker\u2019s fees from Agaplesion Frankfurter Diakonie Kliniken gemeinn\u00fctzige GmbH, Almirall, Aphria Deutschland GmbH, Arbeitsgemeinschaft Cannabis als Medizin (ACM), Astra Zeneca, Bedrocan, Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), Camurus, canymed GmbH, CEREBRO SPAIN BIDCO S.L, Cogitando GmbH, Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Diplomado Internacional de Endocannabinolog\u00eda (Programa Universitario de Investigaci\u00f3n en Salud - PUIS, UNAM), Dresden International University (DIU), Emalex, EpiCampusNord, Eurox Deutschland GmbH, Ever pharma GmbH, Four20 Pharma, Georgia Medical Cannabis Project (GMCP), Grow Group PLC, Landesamt f\u00fcr Soziales, Jugend und Versorgung Mainz, Hessische Landesstelle f\u00fcr Suchtfragen e.V. (HLS), Landschaftsverband Westfalen-Lippe, LIO Pharmaceuticals GmbH, Medizinischer Dienst Westfalen Lippe, Meinhardt Congress GmbH, PR Berater, Salus gGmbH - Fachklinikum Bernburg, Spectrum Therapeutics GmbH, streamedup! GmbH, Swiss Alpinopharm, SynopticCon GmbH, targoEvent GmbH, Takeda GmbH, Tilray, VFnK \u2013 Verein zur F\u00f6rderung neurologisch Kranker e.V., von Mende Marketing GmbH, Wayland Group, and WeCann. She has received royalties from Deutsches \u00c4rzteblatt, Der Neurologe und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic \u201cThe neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects\u201d, is an associate editor for \u201cCannabis and Cannabinoid Research\u201d and an Editorial Board Member of \u201cMedical Cannabis and Cannabinoids\u201d und \u201cMDPI-Reports\u201d and a Scientific board member for \u201cZeitschrift f\u00fcr Allgemeinmedizin\u201d.Peter Nagy has received consultancy fees from Medice, and conference participation support from Medice, Egis Pharmaceuticals and Medis Hungary. He is currently a principle investigator for a Tourette study on ecopipam sponsored by Emalex.Robert Kr\u00e4mer and Michele Dunlap have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}